Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 0.56 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 5/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30858873 | 1.00 | METAP2 (0.56) | METAP2NOS1AXLHTTIDO1 | |
| SCHEMBL18714303 | 0.80 | METAP2 (0.58) | METAP2IDO1TDO2CYP1A2METTL3 | |
| SCHEMBL30860846 | 0.79 | METAP2 (0.56) | METAP2HTTIDO1TDO2MEN1 | |
| SCHEMBL27228209 | 0.79 | METAP2 (0.56) | METAP2HTTIDO1TDO2MEN1 | |
| SCHEMBL31200266 | 0.79 | METAP2 (0.56) | METAP2AXLIDO1TDO2CYP1A2 | |
| SCHEMBL24455088 | 0.79 | METAP2 (0.56) | METAP2IDO1TDO2CYP1A2METTL3 | |
| SCHEMBL2007139 | 0.76 | IDO1 (0.59) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL29793841 | 0.76 | IDO1 (0.59) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL17875686 | 0.75 | TDO2 (0.66) | METAP2NOS1AXLIDO1TDO2 | |
| SCHEMBL27228483 | 0.72 | NOS1 (0.53) | METAP2NOS1IDO1TDO2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LTD (IE) | 2026-03-05 | — | — | US | disclosed |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2025-12-25 | — | — | US | disclosed |
| US-12358915-B2 | METTL3 inhibitory compounds | STORM Therapeutics Ltd. (GB) | 2025-07-15 | — | — | US | disclosed |
| WO-2024047135-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LIMITED (GB) | 2023-03-16 | — | — | US | disclosed |
| EP-3946618-A1 | METTL3 INHIBITORY COMPOUNDS | Storm Therapeutics Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113905787-A | METTL3 inhibiting compounds | 斯托姆治疗有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020201773-A1 | METTL3 INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-7960563-B2 | Indazoles used to treat estrogen receptor beta mediated disorders | GLAXO GROUP LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| CN-101679288-A | Indazoles for treating estrogen receptor beta mediated diseases | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2118068-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008107455-A1 | INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358915-B2 | METTL3 inhibitory compounds | METTL3, METTL16, DIMT1 | METAP2 50/4885NOS1 1520/4885AXL 4231/4885 |
| US-20260060961-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | KRAS, NRAS, HRAS | METAP2 4271/4885NOS1 3015/4885AXL 678/4885 |
| US-20250388577-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, RNMT, TPMT | METAP2 203/4885NOS1 550/4885AXL 3307/4885 |
| US-20100087502-A1 | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders | GPER1, ESR2, ESRRB | METAP2 2445/4885NOS1 2587/4885AXL 3533/4885 |
| US-20230085408-A1 | METTL3 INHIBITORY COMPOUNDS | METTL3, METTL16, DIMT1 | METAP2 50/4885NOS1 1520/4885AXL 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.